Peyronie's disease

  • 10 Years' Plaque Incision and Vein Grafting for Peyronie's Disease: Does Time Matter?

    Surgical correction is advocated in patients with stable Peyronie's disease (PD) and severe curvature of the penis. Contemporary series demonstrate favorable outcomes based on relatively short follow-up periods.

    Published February 10, 2016
  • A Comparative Study Between 2 Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease.

    Although many grafts have been used for plaque incision with grafting (PIG) and penile prosthesis (PP) implantation, there is no evidence that favors 1 specific graft over another.

    To compare fibrin-coated collagen fleece (TachoSil; Baxter International, Deerfield, IL, USA) with porcine small intestinal submucosa (SIS; Cook Biotech, West Lafayette, IN, USA) as grafts.

    Published May 27, 2018
  • A prospective multicentric international study on the surgical outcomes and patients' satisfaction rates of the 'sliding' technique for end-stage Peyronie's disease with severe shortening of the penis and erectile dysfunction.

    OBJECTIVES - To report the results from a prospective multicentric study of patients with Peyronie's disease (PD) treated with the 'sliding' technique (ST).

    PATIENTS AND METHODS - From June 2010 to January 2014, 28 consecutive patients affected by stable PD with severe penile shortening and end-stage erectile dysfunction (ED) were enrolled in three European PD tertiary referral centres.

    Published February 10, 2016
  • A prospective multicentric international study on the surgical outcomes and patients' satisfaction rates of the "Sliding Technique" for end-stage Peyronie's disease with severe shortening of the penis and erectile dysfunction.

    OBJECTIVE - Urethral recurrence (UR) after radical cystectomy is rare but associated with high mortality. With the recently increased use of orthotopic bladder substitution and the questionable benefit of prophylactic urethrectomy, identification of patients at high risk of recurrence, management of the remnant urethra, and treatment of recurrence become critical questions.

    Published November 16, 2015
  • A Worldwide Survey on Peyronie's Disease Surgical Practice Patterns Among Surgeons.

    Despite published guidelines on Peyronie's disease (PD), there are limited data on actual surgical practice among surgeons.

    To evaluate the surgical practice patterns in PD among surgeons from different continents and members of various sexual medicine societies.

    Published March 31, 2018
  • Adjuvant Maneuvers for Residual Curvature Correction During Penile Prosthesis Implantation in Men with Peyronie's Disease.

    INTRODUCTION - The surgical treatment of comorbid erectile dysfunction and Peyronie's disease has long included the implantation of an inflatable penile prosthesis as well as a number of adjuvant maneuvers to address residual curvature after prosthesis placement.

    Published November 18, 2015
  • Alternative Splicing of IGF1 Gene as a Potential Factor in the Pathogenesis of Peyronie's Disease.

    Peyronie's disease (PD) is a fibrotic entity for which the pathogenetic mechanism remains unclear and if resulting in severe deformity, its treatment is only surgical. In this study we investigated the possible role of insulin-like growth factor 1 (IGF1) expression in the pathogenesis of PD.

    Published April 24, 2016
  • An Analysis of Case Logs From American Urologists in the Treatment of Peyronie's Disease.

    To review recent trends in the treatment of PD, we assess surgical practice patterns of urologists in the United States with emphasis on specialty training, demographics, and temporal changes.

    Six month case log data of American urologists between 2004 and 2013 was obtained from the American Board of Urology.

    Published October 26, 2015
  • AUA 2013 - Podcast: Intralesional therapy with collagenase clostridium histolyticum (CCH), a promising, non-surgical, minimally-invasive option for the treatment of Peyronie's disease

    SAN DIEGO, CA USA (UroToday.com) - In this podcast, Dr. Wayne J. G. Hellstrom from Tulane University School of Medicine in New Orleans gives a summary of some of the key points and discusses results from the Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies (IMPRESS) I and II phase three trials.

    Published May 7, 2013
  • AUA 2013 - Slide Presentation: Composite responders showed improvement in both penile curvature deformity and symptom bother in two large double-blind, randomized, placebo-controlled phase 3 studies of collagenase clostridium histolyticum in the treatment

    SAN DIEGO, CA USA (UroToday.com) - Full title: AUA 2013 - Slide Presentation: Composite responders showed improvement in both penile curvature deformity and symptom bother in two large double-blind, randomized, placebo-controlled phase 3 studies of collagenase clostridium histolyticum in the treatment of Peyronie’s disease

    Published May 6, 2013
  • Cavernoplasty with oral mucosa graft for the surgical treatment of Peyronie's disease.

    Peyronie's disease is a disorder of the tunica albuginea and causes penile curvature, requiring surgical correction when the deformity impedes penetration.

    Retrospective analysis of the short-term results (penile length, angle of curvature and erectile function) of treating Peyronie's disease in 10 patients through cavernoplasty with oral mucosa graft.

    Published February 16, 2016
  • Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners.

    Collagenase Clostridium histolyticum (CCH) intralesional injection was efficacious for the management of Peyronie's disease (PD) in the double-blinded, randomized, placebo-controlled Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies I and II (IMPRESS I and II).

    Published April 16, 2017
  • Collagenase Clostridium histolyticum for the pharmacological management of Peyronie's disease.

    Peyronie's disease (PD) is defined as the abnormal accumulation of connective tissue in the tunica albuginea of the penis, and is an ongoing physical and psychological challenge for thousands of Americans.

    Published September 29, 2015
  • Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study.

    Peyronie's disease (PD) is a common condition which results in penile curvature making sexual intercourse difficult or impossible. Collagenase clostridium histolyticum (CCH) is the first licensed drug for the treatment of PD and is indicated in patients with palpable plaque and curvature deformity of at least 30° of curvature.

    Published May 13, 2018
  • Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol.

    Peyronie's disease (PD) is a common condition that results in penile deformity, which makes sexual intercourse difficult or impossible, and causes psychological, emotional, and relationship difficulties for the man affected and his partner.

    Published September 16, 2017
  • Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact.

    Peyronie's disease (PD) is a connective tissue disorder resulting in the abnormal accumulation of type I to III collagen, fibrin, and disorganized elastic fibers in the tunica albuginea of the penis.

    Published April 30, 2017
  • Comparative Analysis of Tunical Plication vs. Intralesional Injection Therapy for Ventral Peyronie's Disease.

    Approximately 10% of Peyronie's disease (PD) patients present with ventral curvatures and, as such, there is a paucity of data describing the optimal approach for treatment.

    This study aims to compare the outcomes of surgery (tunical plication [TP]) and intralesional injection (ILI) therapy (interferon-α2b) in men with ventral PD.

    Published December 22, 2015
  • Contemporary Review of Grafting Techniques for the Surgical Treatment of Peyronie's Disease.

    Peyronie's disease (PD) is a benign fibrotic disorder of the tunica albuginea of the penis, which can cause penile pain, curvature, shortening, erectile dysfunction, and psychological distress. Surgery is indicated when penile curvature prevents satisfactory sexual intercourse.

    Published March 18, 2017
  • Contemporary Review of Peyronie's Disease Treatment

    To analyze the literature on the current treatment options for Peyronie's disease (PD).

    Intracavernosal injection therapy using collagenase clostridium histolyticum (CCH) has been widely adopted since its FDA approval in 2013.

    Published June 2, 2018
  • Contemporary Review of Treatment Options for Peyronie's Disease.

    Peyronie's disease (PD) is a penile wound-healing disorder resulting in fibrotic plaque in the tunica albuginea, likely resulting from micro trauma. Due to variable disease presentations, a myriad of proposed treatment options, physician misconceptions about the disorder, and severe psychological distress in afflicted patients; PD can be a difficult to manage entity.

    Published February 29, 2016
  • Critical Appraisal and Review of Management Strategies for Severe Fibrosis During Penile Implant Surgery.

    INTRODUCTION - Penile corporal fibrosis represents a challenging clinical scenario for surgeons placing penile prostheses (PP). Because of its rarity, a small number of series with limited follow-up have reported outcomes in this cohort.

    Published November 19, 2015
  • Devices for penile traction: the long and winding road to treating Peyronie's disease.

    Penile Traction Therapy (PTT) is increasingly being recognized as a viable non-surgical approach to Peyronie's Disease (PD). The goal of this article is to review the current literature on PTT with attention to traction protocols, devices, and outcomes.

    Published July 23, 2018
  • Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study.

    Several intralesional therapeutic protocols have been proposed for the treatment of Peyronie's disease. Among all, hyaluronic acid (HA) and verapamil have been differently tested. We aimed to evaluate the efficacy of intralesional verapamil (ILVI) compared with intralesional HA in patients with early onset of Peyronie's disease (PD).

    Published August 5, 2017
  • Evidence-Based Management Guidelines on Peyronie's Disease.

    Despite recent advances in our knowledge and treatment strategies in Peyronie's Disease (PD), much remained unknown about this disease.

    To provide a clinical framework and key guideline statements to assist clinicians in an evidence-based management of PD.

    Published June 30, 2016
  • Failure to attain stretched penile length after intracavernosal injection of a vasodilator agent is predictive of veno-occlusive dysfunction on penile duplex Doppler ultrasonography.

    Penile duplex Doppler ultrasound (PDDU) assesses the etiology of erectile dysfunction. Peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI) are common PDDU parameters.

    Published August 11, 2015
  • Female Partners of Men With Peyronie's Disease Have Impaired Sexual Function, Satisfaction, and Mood, While Degree of Sexual Interference Is Associated With Worse Outcomes.

    Peyronie's disease (PD) causes penile deformity and can result in sexual dysfunction and psychological distress. Currently, nothing is known about the psychosexual impact on the partners of men with PD.

    Published May 24, 2016
  • Grafts for Peyronie's disease: a comprehensive review.

    The difficulty implicit in combining all the characteristics that an ideal patch to treat Peyronie's disease with a lengthening procedure should have, together with the challenges of comparing results from different series, means that the ideal patch has yet to be determined.

    Published December 24, 2017
  • Increased Risk of Incident Disease in Men with Peyronie's Disease: Analysis of U.S. Claims Data.

    The subsequent health risks associated with Peyronie's disease (PD) are unknown.

    This cohort study assesses the risk of developing auto-immune conditions and common chronic health conditions after a diagnosis of PD.

    Published June 18, 2018
  • Inflatable Penile Prosthesis Placement, "Scratch Technique", and Postoperative Vacuum Therapy as a Combined Approach in the Definitive Treatment of Patients with Peyronie's Disease.

    Peyronie's disease (PD) is a devastating condition resulting in penile deformity, erectile dysfunction (ED), pain and emotional distress. This prospective two institution study evaluates a multimodal surgical and mechanical combined approach in the definitive treatment of PD and concomitant ED.

    Published April 22, 2018
  • Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells.

    The activation of tunica albuginea myofibroblasts (MFs) serves an essential role in Peyronie's disease (PD). Increasing evidence has reported that adipose tissue-derived stem cells (ADSCs) have been demonstrated to attenuate the symptoms of PD in animal models.

    Published December 13, 2017
  • Intralesional collagenaseClostridium histolyticumin the management of Peyronie's disease: current best practice.

    The use ofClostridium histolyticumcollagenase (CCH) has become increasingly widespread for the treatment of Peyronie's disease (PD) in recent years. Numerous trials have confirmed both its safety and efficacy in appropriately selected patients with this condition.

    Published March 24, 2018
  • Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study.

    INTRODUCTION - Hyaluronic acid has been shown to be efficacious in decreasing scar formation, inflammation, and oxidative stress.

    AIM - To assess the efficacy of intralesional injection of hyaluronic acid in patients affected by Peyronie's disease.

    Published March 21, 2016
  • Levels of serum trace elements in patients with Peyronie.

    The etiology of the disease of Peyronie is not certainly known. However, penile micro traumas are thought to be important in the pathogenesis of Peyronie's disease (PD) in genetically predisposed individuals.

    Published June 2, 2018
  • Malleable Penile Implant Is an Effective Therapeutic Option in Men With Peyronie's Disease and Erectile Dysfunction.

    The inflatable penile prosthesis (IPP) is typically the preferred implant for Peyronie's disease (PD) and malleable penile prostheses (MPPs) have been discouraged.

    To evaluate the effectiveness and patient satisfaction of the MPP vs IPP in patients with PD.

    Published January 21, 2018
  • Objective Assessments of Peyronie's Disease.

    Penile deformity is the most obvious manifestation of Peyronie's disease (PD) and key to determining the optimal method of treatment. Other aspects of PD to consider include plaque size, location, and density; amount of calcification; erection quality; disease progression; and penile anatomy.

    Published March 5, 2018
  • Outcomes of Surgical Management of Men with Peyronie's Disease with Hourglass Deformity.

    OBJECCTIVE - To investigate the outcomes of two surgical interventions for Peyronie's disease (PD) with hourglass deformity: partial excision and grafting (PEG) or inflatable penile prosthesis (IPP) implantation.

    Published February 23, 2016
  • Patient-reported long-term sexual outcomes following plication surgery for penile curvature: A retrospective 58-patient study.

    To evaluate long-term sexual function results following plication surgery for the correction of penile curvature using patient questionnaires.

    We performed a single-center, retrospective study in a cohort of patients with Peyronie's disease or congenital penile curvature.

    Published November 29, 2016
  • Penile Plication With or Without Degloving of the Penis Results in Similar Outcomes.

    Penile plication techniques with or without degloving offer a minimally invasive option for the treatment of penile curvature.

    To review the outcomes of penile plication surgery and patient satisfaction with and without degloving of the penis.

    Published July 28, 2017
  • Penile Prosthesis Implantation in Patients With Peyronie's Disease: Results of the PROPPER Study Demonstrates a Decrease in Patient-Reported Depression.

    Although there is a strong correlation between erectile dysfunction and Peyronie's disease (PD), there are limited data on the efficacy and satisfaction of inflatable penile prosthesis (IPP) placement in this population.

    Published April 15, 2018
  • Penile Reconstructive Surgery in Peyronie Disease: Challenges in Restoring Normal Penis Size, Shape, and Function.

    To provide an overview of current approaches to penile reconstructive surgery in Peyronie disease (PD), and to discuss the challenges in restoring normal penile size and function.

    A systematic literature search was conducted to identify the published literature relevant to PD and penile reconstructive surgery.

    Published April 7, 2018
  • Peyronie's Disease

    History and Background:

    • The first description of Peyronie's disease is credited to Francois Gigot de la Peyronie in 1743.
    • No consensus exists with regard to the etiology, prevalence and treatment of the condition.  
    • Peyronie's disease is associated with Dupuytren disease. Dupuytren disease has a familial pattern known to be transmitted in an autosomal dominant pattern. 
    • Thirty percent to 40% of men with Peyronie's disease will also have Dupuytren disease.

    Eitiology and Natual History:

    • Peyronie's disease presents as a variety of deformities of the penis. 
    • The symptomatic incidence has been estimated at 1%, but data indicates that the incidence is increasing and now can be estimated conservatively at 5% and some recent estimates are  8.9% to 13%.
    • Peyronie’s disease is defined by the presence of an inflammatory reaction and eventual fibrotic plaque development within the tunica albuginea or of the corpora cavernosa.
    • This plaque, which is palpable on physical examination in established cases, is associated with the common presenting symptoms of Peyronie’s disease, including pain with erection, curvature or deformity of the erect penis and erectile dysfunction (ED).
    • Plaque formation is thought to be the result of trauma, to the erect or semi-erect penis, which is propagated by aberrant would healing.
    • Reports of an association between Peyronie’s disease and Dupuytren’s contracture, plantar fascial contracture, tympanosclerosis, diabetes, urethral instrumentation, autoimmune disorders and as an inherited form of the disorder suggest that a multifactorial etiology is likely.
    • Disease development is described in two phases. 
      • The first phase is associated with painful erections and changing deformity of the penis. 
      • The second phase,is characterized by the disappearance of painful erections, if previously present, and a stability in the disease process.
    • Most patients do not require surgery. 
    • Patient's do require reassurance and education. 
    • Surgery for Peyronie's disease is considered palliation for the mechanical effects of the disease.
    • Peyronie's disease has been related to a number of conditions. The strongest relation is to Dupuytren disease.
    • The development of Peyronie's disease does seem to be related to the unique anatomy of the tunica albuginea and its relationship to the septal fibers.
    • Buckling trauma of the penis, usually occurring during intercourse, has been implicated in the development of Peyronie's disease. 
    • TGF-β has been found to be related to the disordered healing process that leads to the scarring of the Peyronie's plaque. 
    • Failure of downregulation of a number of “antifibrotic” factors has been implicated.


    • The presenting symptoms of Peyronie's disease include, in many patients, penile pain with erection; penile deformity, both flaccid and erect; shortening with and without an erection; plaque or indurated areas in the penis; and, in many patients, erectile dysfunction. 
    • On physical examination, virtually all patients have either a well-defined plaque or an area of induration that is palpable. 
    • The plaque is usually on the dorsal surface of the penis, intimately associated with the insertion of the septal fibers.
    • Spontaneous improvement in pain virtually always occurs as the inflammation resolves.

    Patient Evaluation:

    • Patients with Peyronie's disease present with a variety of deformities of the penis. 
    • Most have noted an indurated area in the penis that has been identified as the plaque. 
    • Many patients have noticed erectile dysfunction. 
    • All patients must be evaluated with a medical history, as well as a detailed psychosexual history. 
    • Approximately one third of the patients will develop dystrophic calcification in the plaque that can be demonstrated by ultrasonography or plain radiography. 
    • The place for MRI in the evaluation of Peyronie's plaque has not been defined, nor has the place for vascular testing been clearly defined. 
    • However, most urologists would agree that in patients who are to be operated on, vascular testing to stratify the vascular parameters of erectile function is a necessity. 
    • Once all of the data have been assembled, individualization with regard to the patient's requirements, findings, and assessment is imperative.

    Medical Management:

    • The efficacy of medical management of Peyronie's disease is difficult to determine because there are few RCT. 
    • Vitamin E has been used historically, and while supplementation has been studied for decades, and some success has been reported in older trials, those results have not been reproducible in RCT.
    • A combination of Vitamin E and colchicine has shown some promise in delaying progression of the condition.
    • Potassium aminobenzoate, in a small study, was found to reduce plaque size, not curvature, and thus in that study was found “efficacious.” However, the side effects make it difficult to tolerate.
    • A number of intralesional protocols have been proposed. 
    • The use of verapamil as an intralesional agent has been studied. A prospective study did show decrease in curvature in about 80% of the patients. 
    • Injections to plaques (scar tissue formed by the inflammation) with Verapamil may be effective in some patients, but a recent placebo controlled trial failed to show a significant improvement. 
    • So there are conflicting outcomes reported.
    • Interferon-alpha-2b has been proposed in recent publications.
    • Radiation therapy should be avoided. 
    • The vacuum erection device has not been adequately studied.
    • Penile traction has not been adequately studied.
    • The place of extracorporeal shockwave therapy has likewise not been adequately determined.

    The use of collagenase as an intralesional agent has been subjected to a number of double-blind placebo-controlled protocols, and, in all, efficacy was suggested. Collagenase is currently not available as an approved treatment and remains in development.  


    • The consensus committee on Peyronie's disease at the World Health Organization Second International Consultation on Sexual Dysfunctions stated that the penile prosthesis is a reliable option for the older man with vascular impairment, erectile dysfunction, and acquired deformity of the penis.
    • It is not the only treatment of Peyronie's disease but rather a prudent treatment for the patient with significant erectile dysfunction in association with Peyronie's disease. 
    • Hydraulic prostheses are preferred, and those prostheses that have true controlled expansion cylinders have been shown to provide better results.


    • Brock G, Lue TF: Peyronie's disease, a modified treatment. Urology 1993; 42:300-304.
    • Brock G, Hsu GL, Nunes L, et al: The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 1997; 157:276-281.
    • Carson CC, Jordan GH, Gelbard MK: Peyronie's disease: new concepts in etiology, diagnosis and treatment. Contemp Urol 1999; 11:44-64.
    • Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Adva Urol 2011;282503.
    • Hellstrom WJ: History, epidemiology and clinical presentation of Peyronie's disease [review]. Int J Impot Res 2003; 15(Suppl.):S91-S92. S121-4.
    • Levine LA, Greenfield JM: Establishing a standardized evaluation of the man with Peyronie's disease [review]. Int J Impot Res 2003; 15(Suppl.):S103-S112.
    • Levine LA. Peyronie's disease and erectile dysfunction: Current understanding and future direction. Indian J Urol 2006;22:246-50.
    • Mulhull JP, Creech SD, Boorjian SA, et al: Subjective and objective analysis of the prevalence of peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171:2350 - 53.
    • Mynderse LA, Monga M (October 2002). "Oral therapy for Peyronie's disease". International Journal of Impotence Research 14 (5): 340–4.
    • Nyberg Jr LM, Bias WB, Hochbert MC, Walsh PC: Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982; 128:48-51.
    • O’Brien K, Parker M, Guhring P, et al: Analysis of the natural history of Peyronie's disease [abstract 69]. J Sex Med 2004; 1(Suppl. 1):50.
    • Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al: Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003; 91:522-524.
    • Riedl CR, Sternig P, Gallé G, et al. (October 2005). "Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study". European Urology 48 (4): 656–61.
    • Trost LW, Gur S, Hellstrom WJ (2007). "Pharmacological Management of Peyronie's Disease". Drugs 67 (4): 527–45.
    Published October 1, 2014
  • Peyronie's disease and Dupuytren's contracture secondary to topical timolol.

    Topical beta-blockers are a proven and safe medication used in the treatment of glaucoma and ocular hypertension. Local and systemic side effects are, however, well documented. Systemic side effects can include severe cardio-respiratory impairment, endocrine dysfunction, as well as headache and hyper-somnolence.

    Published February 12, 2018
  • Peyronie's disease: What's around the bend?

    INTRODUCTION - Peyronie's disease (PD) is a fibrotic diathesis of the tunica albuginea that results in penile plaque formation and penile deformity, negatively affecting sexual and psychosocial function of both patients and their partners.

    Published March 30, 2016
  • Phase I and phase II clinical trials for the treatment of male sexual dysfunction - A systematic review of the literature.

    Introduction - The prevalence of sexual dysfunctions has increased over the last decades; despite a number of available treatments for erectile dysfunction (ED), premature ejaculation (PE) and Peyronie's disease (PD), still several unmet therapeutic needs deserve to be fulfilled.

    Published July 9, 2018
  • Plaque calcification: An important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie's Disease.

    To compare outcomes of men with or without calcified plaques undergoing collagenase clostridium histolyticum (CCH) injections for Peyronie's Disease (PD) and identify predictors of CCH success.

    From March 2014 through January 2017, data were prospectively collected on 192 patients who underwent 1-4 cycles of CCH for the treatment of PD.

    Published June 26, 2018
  • Practical Computerized Solution for Incision and Grafting in Peyronie's Disease.

    INTRODUCTION - Penile curvature correction with plaque incision and graft (PIG) increases the risk of erectile dysfunction (ED) and is associated with mechanical and geometric abnormalities.

    AIMS - The aim of this study was to create and validate a new PIG technique using minimum graft area to correct simple or complex penile curvature with or without hourglass deformity, while avoiding mechanical and geometric abnormalities.

    Published January 26, 2016
  • Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie's disease.

    Interferon (IFN)-α2b in Peyronie's disease (PD).

    This study aims to evaluate clinical efficacy of the IFN-α2b in both subjective and objective manner for the treatment of PD and compared with previously used intralesional verapamil in terms of cost-benefit analysis.

    Published May 6, 2018
  • Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-β/SMAD signalling pathway.

    Peyronie's disease (PD) is a fibrotic disorder of the tunica albuginea (TA). This study aimed to determine the therapeutic effects of a vacuum erection device (VED) in an animal model of PD and explore the possible mechanisms.

    Published July 1, 2018
  • Review of Management Options for Patients With Atypical Peyronie's Disease.

    Peyronie's disease (PD) is a wound-healing disorder of the tunica albuginea often associated with penile deformity. Less commonly, patients with PD might display atypical presentations such as ventral curvature, hourglass deformity, significantly shortened penis, and/or multiplanar curvature.

    Published September 6, 2016
  • Role of extracorporeal shock wave therapy in management of Peyronie's disease: A preliminary report.

    Peyronie's Disease (PD) is a disease causing psycho social trauma to the patient. Multiple treatment options are available with variable results. Extra Corporeal Shock Wave Therapy (ESWT) is a new insight into the non invasive modality of management.

    Published January 9, 2017

Page 1 of 2